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Inhibition of CDK activity and
PCNA-dependent DNA replication by
p21 is blocked by interaction with the
HPV-16 E7 oncoprotein
Jens Oliver Funk,1 Shou Waga,2 Jo Beth Harry,1 Erik Espling,1 Bruce Stillman,2 and
Denise A. Galloway1,3
1Program in Cancer Biology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington 98109 USA; 2Cold
Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA
p21 inhibits cyclin-dependent kinase (CDK) activity and proliferating cell nuclear antigen (PCNA)-dependent
DNA replication by binding to CDK/cyclin complexes and to PCNA through distinct domains. The human
papillomavirus (HPV)-16 E7 oncoprotein (16E7) abrogated a DNA damage-induced cell cycle arrest in vivo,
despite high levels of p21. Using cell lysates and purified proteins we show that 16E7 prevented p21 both from
inhibiting CDK2/cyclin E activity and PCNA-dependent DNA replication, whereas the nononcogenic HPV-6
E7 had reduced effects. Inactivation of both inhibitory functions of p21 was attained through binding between
16E7 and sequences in the carboxy-terminal end of p21 that overlap with the PCNA-binding site and the
second p21 cyclin-binding motif. These data imply that the carboxyl terminus of p21 simultaneously
modulates both CDK activity and PCNA-dependent DNA replication and that a single protein, 16E7, can
override this modulation to disrupt normal cell cycle control.
[Key Words: CDK inhibitors; p21CIP1/WAF1/SDI1; DNA replication; PCNA; cell cycle arrest; HPV-16 E7;
HPV-6 E7]
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Regulation of cyclin-dependent kinase (CDK) activities
occurs at several levels, including binding of CDK in-
hibitors to the CDK/cyclin complex (for review, see
Morgan 1995). CDK inhibitors are involved in cell cycle
arrest in response to various antimitogenic signals (for
review, see Sherr and Roberts 1995). One member of the
CIP/KIP family of CDK inhibitors, p21CIP1/WAF1/SDI1
(El-Deiry et al. 1993; Gu et al. 1993; Harper et al. 1993;
Xiong et al. 1993a; Noda et al. 1994), is a transcriptional
target of p53 and is a critical determinant of the G1 arrest
in response to DNA damage (Dulic et al. 1994; Brugaro-
las et al. 1995; Deng et al. 1995; Waldman et al. 1995).
However, p21 also responds to other signals indepen-
dently of p53 and has been implicated in terminal differ-
entiation and senescence (Noda et al. 1994; Halevy et al.
1995; Macleod et al. 1995; Parker et al. 1995). Under
some conditions, p21 can function as an adaptor protein
in the assembly of CDK/cyclin complexes (Xiong et al.
1993b; Harper et al. 1995; LaBaer et al. 1997).
p21 is an unusual CDK inhibitor; in addition to the
well-defined amino-terminal cyclin and CDK-binding
motifs (Chen et al. 1995; Luo et al. 1995; Nakanishi et al.
1995) a second cyclin binding site is located near the
carboxyl terminus (Adams et al. 1996; Ball et al. 1996;
Chen et al. 1996), partially overlapping the domain that
binds to the proliferating cell nuclear antigen (PCNA;
Warbrick et al. 1995; Gulbis et al. 1996). PCNA, an aux-
iliary factor for DNA polymerase d and e, facilitates load-
ing of the polymerases onto DNA templates and in-
creases their activity in both DNA replication and repair.
Through an interaction with PCNA, p21 inhibits PCNA-
dependent DNA replication (long-range DNA synthesis;
Flores-Rozas et al. 1994; Waga et al. 1994b), whereas
PCNA-dependent nucleotide excision–repair (short-
patch DNA synthesis) is not inhibited (Li et al. 1994,
1996; Shivji et al. 1994). Thus, p21 may mediate the co-
ordination between cell cycle progression, DNA replica-
tion, and DNA repair (Li et al. 1994; Waga et al. 1994b),
but the exact contribution of each of the inhibitory ac-
tivities of p21 to cell cycle arrest in vivo is unclear.
The E7 oncoprotein of the cancer-associated human
papillomaviruses (HPVs) such as HPV-16 (16E7) has been
shown to overcome a DNA damage-induced G1 cell
cycle arrest, whereas E7 from the generally benign HPV
types like HPV-6 (6E7) has not (Demers et al. 1994;
Slebos et al. 1994). The mechanisms involved in the ab-
rogation of G1 cell cycle arrest by 16E7 are incompletely
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understood, and subsequent analysis was mostly focused
on the inactivation of the retinoblastoma protein (RB) by
16E7. Binding of 16E7 to RB obviates the requirement for
cyclin D-associated kinase activity to phosphorylate RB
and leads to the release of E2F transcription factors that
activate S-phase genes (DeGregori et al. 1995), including
cyclin E (Zerfass et al. 1995), which is necessary for the
G1-to-S-phase transition (Ohtsubo et al. 1995; for review,
see Reed 1996); cyclin A, which is required during S
phase; and PCNA. Elevation of these cell cycle proteins
may contribute to bypassing G1 arrest signals. Addition-
ally, 16E7 expression results in reduced amounts of RB
protein (Demers et al. 1994; Boyer et al. 1996; Jones and
Mu¨nger 1997), though the mechanism is unclear. Nev-
ertheless, studies using mutated E7 or adenovirus E1A
proteins have pointed to additional activities of the viral
oncoproteins, unrelated to RB binding, that are involved
in bypassing growth arrest signals (Abraham et al. 1992;
Missero et al. 1995; Demers et al. 1996).
In this study we demonstrate that 16E7 blocks the
ability of p21 to inhibit CDK activity as well as PCNA-
dependent DNA replication through direct binding to
the carboxyl terminus of p21. We propose that interac-
tions with the carboxyl terminus of p21 modulate both
its CDK- and PCNA-inhibitory functions.
Results
Effects of 16E7 on CDK activity and PCNA-dependent
DNA replication
Human keratinocytes were infected with a retroviral
vector expressing 16E7, treated with actinomycin D for
24 hr to induce DNA damage, and extracts were pre-
pared. Cell cycle progression was monitored by flow cy-
tometry. Our previous studies (Demers et al. 1994)
showed that vector-infected cells arrested with an in-
creased G1 population and depletion of S-phase cells to
3%–15% of the number of S-phase cells in the untreated
population, whereas 16E7-expressing cells consistently
retained 60%–90% of their S-phase population after
DNA damage. Figure 1A demonstrates that DNA dam-
age resulted in induction of p53 and p21 in both popula-
tions of cells; however, 16E7-expressing cells remained
in the cell cycle despite induction of p21. Cyclin E-asso-
ciated CDK activity was elevated in untreated 16E7-ex-
pressing cells compared to vector-infected cells, and no-
tably actinomycin D-treated, 16E7-expressing cells re-
tained 50% kinase activity of untreated cells (Fig. 1A).
These results indicated that 16E7-expressing cells were
able to abrogate the CDK-inhibitory function of p21.
The mechanism by which 16E7 bypassed p21 inhibi-
tion of CDK activity in in vivo systems was not clear and
might involve the ability of 16E7 to release E2F and thus
elevate cyclin E levels (Zerfass et al. 1995) to titrate the
increase in p21, or to reduce levels of RB protein (Demers
et al. 1994; Jones and Mu¨nger 1997). However, none of
these explanations was fully consistent with the obser-
vation that some mutants that bind RB remained unable
to inactivate p21 in vivo (Demers et al. 1996). The over-
expression of CDK2/cyclin E only resulted in 60% of the
activity of 16E7 in bypassing a p21-mediated cell cycle
arrest (S.A. Foster and D.A. Galloway, unpubl.). Taken
together, these data suggested that 16E7 used an addi-
tional pathway to inactivate p21.
Figure 1. Effect of HPV-16 E7 and HPV-6 E7 on inhibition of
CDK activity by p21 in vivo and in vitro. (A) Human keratino-
cytes were infected with retroviral constructs alone (LXSN) or
expressing 16E7 and were treated with actinomycin D (act D)
for 24 hr. Cells were harvested, and a fraction was used for cell
cycle analysis by flow cytometry to determine the fraction of
S-phase cells (top); the remainder was used to prepare extracts
for immunoblots with anti-p53 or anti-p21 antibodies (middle)
and in vitro kinase assays after anti-cyclin E immunoprecipita-
tions (bottom). (B) Extracts of untreated or actinomycin
D-treated (act D) human keratinocytes (200 µg) were coincu-
bated with GST–16E7 (850 ng); then cyclin E was immunopre-
cipitated [lanes 2–5; (PI) preimmune serum in lane 1] and kinase
assays were performed for 20 min at 30°C using histone H1
(HH1) as a substrate. (C) Purified recombinant His–cyclin
E/CDK2 complexes, produced in baculovirus-infected cells,
were coincubated with His–p21 (10 ng) alone or with His–p21
preincubated with increasing amounts (20 and 200 ng) of His–
16E7 (top) or His–6E7 (bottom), and kinase assays were per-
formed.
Inactivation of p21 by HPV-16 E7
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To determine whether 16E7 could directly affect p21-
inhibited CDK complexes, extracts of untreated or acti-
nomycin D-treated keratinocytes were mixed with glu-
tathione S-transferase (GST)–16E7 fusion proteins in
vitro. Protein 16E7 effectively restored the inhibited
(15% of control; Fig. 1B, lane 4) CDK2/cyclin E activity
(90% of control; Fig. 1B, lane 5) and also elevated CDK2
activity slightly in extracts of untreated cells (120% of
control; Fig. 1B, lane 3). To analyze whether the reversal
of p21 inhibition of CDK activity by 16E7 directly in-
volved the CDK/cyclin/p21 complex or required other
16E7-associated proteins such as p107, purified recombi-
nant, histidine-tagged (His)–cyclin E/CDK2 was inhib-
ited by His–p21 (Fig. 1C, lanes 1,2). Addition of purified
His–16E7 restored the p21-inhibited CDK2 activity in a
dose-dependent manner, whereas His-6E7 had greatly re-
duced effects (Fig. 1C).
Reversal of the effect of p21 on CDK activity by 16E7
may contribute to HPV DNA replication by promoting
the G1-to-S-phase transition. However, viral DNA repli-
cation requires PCNA, and p21 also blocks PCNA-de-
pendent DNA replication. Therefore, the effect of 16E7
on the p21-mediated inhibition of PCNA-dependent
DNA replication was examined in vitro. His–16E7 effec-
tively abrogated the inhibition by p21 of PCNA-depen-
dent DNA synthesis (Fig. 2A) and also SV40 DNA repli-
cation with crude cell extracts (Fig. 2B) in a dose-depen-
dent manner, whereas His–6E7 had only marginal
effects. The effects of the His–E7 proteins on SV40 rep-
lication were also analyzed quantitatively [deoxy AMP
(dAMP) incorporation] and paralleled the results from
the purified replication system (data not shown). The
amounts of E7 proteins used were based on this quanti-
tation. Proteins 16E7 and 6E7 did not affect SV40 DNA
replication in the absence of p21 (data not shown). Im-
portantly, the process of SV40 DNA replication was fully
recovered by 16E7, as completely replicated products
(discrete bands of topoisomers) and late replication in-
termediates (smears above the 4.4-kb marker; Prelich
and Stillman 1988; Waga et al. 1994b) were generated
(Fig. 2B). In this assay, 6E7 had a detectable, dose-depen-
dent effect on the generation of replication products, but
it was greatly reduced compared to the activity of 16E7.
Interaction between p21 and 16E7
The ability of 16E7 to block p21-mediated inhibition of
CDK activity and DNA replication in purified systems
suggested that 16E7 might interact directly with p21.
This possibility was tested in binding assays with puri-
fied or in vitro-translated and -labeled (IVT) proteins.
GST–16E7 bound His–p21 (Fig. 3A), IVT p21 (Figs. 4A
and 5A), IVT p27KIP1, and IVT p57KIP2 (data not shown),
but not His–CDK2 or His–cyclin E (Fig. 3A), or IVT
p16INK4a (data not shown). Reciprocally, GST–p21 bound
His–16E7 (Fig. 5B) and IVT 16E7 but ∼10-fold less well to
IVT 6E7 (Fig. 3B). Under these conditions, the amount of
p21 bound to 16E7 was usually <10% of the input, but
binding was seen even in the presence of 1% NP-40 (data
not shown). To examine whether an interaction between
16E7 and p21 occurred in vivo, actinomycin D-treated,
16E7-expressing keratinocytes were metabolically la-
beled, and extracts were prepared. After a first immuno-
Figure 2. Effect of HPV-16 E7 and HPV-6 E7 on inhibition of
PCNA-dependent DNA replication by p21 in vitro. (A) Increas-
ing amounts of His–16E7 or His–6E7 were preincubated with
(50 ng; closed symbols) or without (open symbols) His–p21 for
60 min at room temperature, then mixed with PCNA (10 ng)
and DNA polymerase d (∼15 ng) and further incubated for 30
min on ice. DNA synthesis was started by adding [a32P]TTP and
oligo(dT)/poly(dA) at 37°C. The amount of DNA synthesis is
expressed as picomoles of TMP incorporated in a 25-µl reaction
in 30 min. (B) Increasing amounts (250 ng, 500 ng, 1 µg) of
His–16E7 or His–6E7 were preincubated with or without His–
p21 (330 ng) for 60 min at room temperature, then mixed with
a 293 human cell extract (19.5 µg) and further incubated for 30
min on ice. DNA replication was started by adding purified T
antigen, an SV40 ori-containing plasmid pSVO11 (Prelich and
Stillman 1988), and nucleotides including [a32P]dATP and in-
cubated at 37°C. Analysis by neutral agarose gel electrophoresis
of purified replication products is shown. Lane 1 shows SV40
DNA replication in the absence of p21 or E7.
Funk et al.
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precipitation with anti-16E7 or anti-p21 antibodies
under low-stringency conditions (data not shown) and
elution of the nonimmunoreactive fraction under high-
stringency conditions (Fig. 3C, lanes 7,8), the associated
proteins were reimmunoprecipitated with a second an-
tibody (anti-p21 and anti-16E7, respectively; Fig. 3C,
lanes 9,10). In both cases, p21 and 16E7 were detected
following reimmunoprecipitation. This experiment
showed that 16E7 and p21 were weakly associated with
each other in vivo. Such an interaction was not seen in
vector-infected cells nor with an irrelevant antibody (Fig.
3C, lanes 1–6).
Amino- and carboxy-terminal fragments of 16E7 were
used to begin to map the p21-interacting domain. The
amino terminus of 16E7 contains motifs for RB binding
and phosphorylation by casein kinase II and shares ho-
mology with the adenovirus E1A-conserved regions I and
II and an analogous region in the SV40 large T antigen;
the carboxyl terminus has a zinc finger motif (for review,
see zur Hausen 1996). Although it does not contain the
high-affinity RB-binding motif, 16E7C(D1–39) retained
the ability to bind to p21, though somewhat reduced in
comparison to intact 16E7, whereas 16E7N(D40–98)
showed no detectable binding (Fig. 4A). Consistent with
this finding, 16E7C at least partially restored kinase ac-
tivity using p21-inhibited purified CDK2/cyclin E com-
plexes (Fig. 4B) and extracts of actinomycin D-treated
cells (data not shown). Although these results demon-
strate that the ability of 16E7 to bind to p21 resides pri-
marily in the carboxyl terminus, the data may point to
an additional role for sequences in the amino terminus.
An analysis of p21 binding to various 16E7 proteins car-
Figure 4. Analysis of binding sites in HPV-16 E7 proteins. (A)
In vitro binding reactions with GST–16E7 mutants (1.5 µg) im-
mobilized on glutathione–Sepharose and IVT p21 or IVT RB
were performed, and the resulting protein complexes were vi-
sualized by Coomassie staining (top) and fluorography (bottom).
Lane 1 represents 10% (IVT p21) or 20% (IVT RB) of the input.
(B) Purified recombinant His–cyclin E/CDK2 complexes were
coincubated with buffer (h) or coincubated with His–p21 (10 ng,
j) alone or with His–p21 preincubated with GST fusion pro-
teins (300 ng; as indicated in A, lanes 2–5), and kinase assays
were performed. The quantitation from PhorphorImager analy-
sis is shown.
Figure 3. Analysis of the HPV-16 E7–p21 interaction in vitro and in vivo. (A) In vitro binding reactions with GST–16E7 or GST (100,
200, 400 ng) immobilized on glutathione–Sepharose and His–p21, His–cyclin E, or His–CDK2 (200 ng) were performed, and the
resulting protein complexes were visualized by Coomassie staining (top) and Western blotting (bottom) with anti-His antibodies. Lane
1 represents 10% of the input. (B) In vitro binding reactions with GST–p21 or GST (1 µg) immobilized on glutathione–Sepharose and
IVT 16E7 or IVT 6E7 were performed, and the resulting protein complexes were visualized by Coomassie staining (top) and fluorog-
raphy (bottom). Lane 1 represents 10% of the input. (C) Actinomycin D-treated, 16E7-expressing keratinocytes were metabolically
labeled with [35S]Protein Labeling Mix, and extracts were prepared. After a first immunoprecipitation (IP) of extracts (900 µg; anti-16E7
or anti-p21 antibody) under low-stringency conditions (data not shown), the associated proteins were eluted under high-stringency
conditions (IP shown after the elution; lanes 7,8) and reimmunoprecipitated with a second antibody (anti-p21 and anti-16E7, respec-
tively; lanes 9,10). Vector (LXSN)-infected cells (lanes 1–4) or an irrelevant antibody (anti-16L1; lanes 5,6) were used as negative
controls. Four percent of the first IP after the high-stringency elution and 100% of the second IP are shown.
Inactivation of p21 by HPV-16 E7
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rying deletions or point mutations has so far been incon-
clusive (data not shown).
Next, mutations in p21 were used to define the region
required for 16E7 binding (summarized in Fig. 5C). The
carboxy-terminal half of p21 [p21C(87–164)] (Fig. 5A,
lanes 5,6), but not the amino-terminal half [p21N(1–90)]
(Fig. 5A, lanes 3,4), bound to 16E7. In accordance with
this result, mutants defective in the cyclin 1 motif
within the amino-terminal half of p21 (Lin et al. 1996) or
in the nearby CDK motif (Nakanishi et al. 1995) bound
efficiently to 16E7 (data not shown). Several carboxy-
terminal mutations in p21 were then tested. Deletion of
6 amino acids [p21(1–158)] did not appreciably reduce
16E7 binding (Fig. 5A, lanes 14,15), but a carboxy-termi-
nal deletion of 16 amino acids [p21(1–148)] eliminated
the binding (Fig. 5A, lanes 12,13). Furthermore, p21(139–
164) bound to 16E7 (Fig. 5B). Therefore, the region of p21
sufficient for the interaction with 16E7 resides in amino
acids 139–158, which interestingly overlaps the PCNA-
binding region (Gulbis et al. 1996) and the second cyclin-
binding region (Fig. 5C; Adams et al. 1996; Ball et al.
1996; Chen et al. 1996).
Role of the carboxyl terminus of p21 in its
inactivation by 16E7
Previous studies have shown that the CDK-inhibitory
function of p21 resides mainly in the amino terminus,
yet our results indicated that the ability of 16E7 to re-
verse p21 inhibiton of CDK activity occurred through its
interaction with the carboxyl terminus of p21. To test
this assumption GST–p21, GST–p21N, and GST–p21C
proteins were used to inhibit CDK2/cyclin E complexes.
16E7 and, to a much lesser extent 6E7, reconstituted
CDK2 activity in the presence of full-length p21, but not
in the presence of p21N, showing that the carboxyl ter-
minus of p21 was required for the 16E7-dependent rever-
sal of CDK inhibition (Fig. 6A, left). p21C did not inhibit
CDK2 activity at low concentrations, which were suffi-
cient for inhibition by p21 or p21N (Fig. 6A, left); how-
ever, at ∼150-fold higher concentrations, p21(139–164)
containing the cyclin 2 site also showed CDK-inhibitory
activity (Adams et al. 1996; Ball et al. 1996), and this
inhibition was overcome by 16E7 (Fig. 6A, right). Fur-
thermore, p21(139–164), which contains the full PCNA-
binding site (Fig. 5B; Warbrick et al. 1995), inhibited
PCNA-dependent DNA synthesis and 16E7 abrogated
this effect (Fig. 6B).
Finally, to begin to understand the mechanism by
which 16E7 blocked the p21 inhibition of CDK activity,
the levels of p21 in anti-CDK2 immunoprecipitates of
reconstituted reactions were assessed. Interestingly, no
change in the level of p21 was seen (Fig. 7A), suggesting
that 16E7 did not appreciably displace p21 from the
CDK2/cyclin E complexes. 16E7 was found to be asso-
ciated with CDK2/cyclin E/p21 complexes, as demon-
strated by immunoblotting of anti-cyclin E immunopre-
cipitates (Fig. 7A). Likewise, 16E7 was detectable in anti-
p21 immunoprecipitates of CDK/cyclin complexes and
vice versa (data not shown). Next, the effect of 16E7 on
Figure 5. Analysis of binding sites in p21 proteins. (A) In vitro
binding reactions with GST–16E7 or GST (1 µg) immobilized on
glutathione–Sepharose and IVT p21 mutant proteins were per-
formed, and the resulting protein complexes were visualized by
fluorography. The mutants used were p21(full-length, 1–164)
(lanes 1,2,7,10,11,16), p21(1–90) (lanes 3,4,8), p21(87–164) (lanes
5,6,9), p21(1–148) (lanes 12,13,17), and p21(1–158) (lanes
14,15,18). Ten percent of the input is shown. (B) In vitro binding
reactions with GST–p21 mutants (100 ng) immobilized on gluta-
thione–Sepharose and His–16E7 (200 ng) or PCNA (40 ng) were
performed, and the resulting protein complexes were visualized
by Western blotting with anti-16E7 (top) and anti-PCNA (bottom)
antibodies. Lane 1 represents 20% of the input. (C) Schematic
representation of p21 and summary of in vitro binding analyses with p21 mutants using purified and IVT proteins. The binding motifs
for cyclin (cyclin 1), CDK, and PCNA are shown as solid boxes, the second cyclin binding motif (cyclin 2) overlapping the PCNA
binding motif is shown as a shaded box.
Funk et al.
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PCNA/p21 complex formation in vitro was examined.
By adding increasing amounts of 16E7 the levels of
PCNA bound to p21 were effectively reduced (Fig. 7B),
suggesting that 16E7 and PCNA were competing for p21
binding.
Discussion
These experiments show that the inhibitory functions of
p21 on both CDK activity and PCNA-dependent DNA
replication can be blocked by 16E7 through mechanisms
involving a direct interaction between 16E7 and the car-
boxyl terminus of p21. Mutagenesis has defined spatially
conserved CDK and cyclin-binding motifs in the amino-
terminal halves of p21, p27, and p57 (Chen et al. 1995;
Luo et al. 1995; Nakanishi et al. 1995), and the crystal-
lographic structure of CDK2/cyclin A/p27N (Russo et
al. 1996) has indicated how these motifs interact with
CDK/cyclin complexes. However, at odds with the
structure is the biochemical evidence that CDK/cyclin
complexes containing a single molecule of p21 are cata-
lytically active (Zhang et al. 1994). Unlike other CIP/KIP
family members, p21 contains a second cyclin binding
motif (Cy2) in the carboxyl terminus, whose core se-
quence RRLIF is related to the RRLFG motif in the first
cyclin-binding site (Cy1; Adams et al. 1996; Ball et al.
1996; Chen et al. 1996). The significance of the Cy2 mo-
tif in inhibiting CDK activity is less well understood.
The p21 Cy2/cyclin interaction was very weak for cyc-
lins E and A and only detectable indirectly by competi-
tion (Chen et al. 1996). Peptides overlapping with Cy2
bound to both CDK4 and cyclin D1, inhibited CDK4/
cyclin D1 and CDK2/cyclin E activity in vitro, and
caused a G1 arrest in vivo (Ball et al. 1996). Additionally,
removal of the amino-terminal 34 amino acids of the
Xenopus homolog of p21, p27Xic1, resulted in a protein
Figure 6. Analysis of the function of the carboxy-terminal do-
main of p21 in the inactivation by HPV-16 E7. (A) Purified re-
combinant His–cyclin E/CDK2 complexes were coincubated
with buffer (lane 1) or GST proteins at low or high concentration
preincubated with buffer (top), His–16E7 (middle), or His–6E7
(bottom). Twenty nanograms of GST or GST–p21 (lanes 2–5), or
2.5 µg of GST or GST–p21(139–164) (lanes 6,7) were used, which
had been preincubated with 400 ng (lanes 2–5) or 6 µg (lanes 6,7)
of His–16E7 or His–6E7, and kinase assays were performed for
20 min at 30°C. (B) Increasing amounts of His–16E7 or His–6E7
were preincubated with GST or GST–p21(139–164) (120 ng).
The subsequent DNA synthesis reaction was carried out as de-
scribed in Fig. 2A.
Figure 7. Analysis of protein complexes in the absence and
presence of HPV-16 E7. (A) Purified recombinant His–cyclin
E/CDK2 complexes were coincubated with His–16E7 and/or
His–p21 as described in Fig. 1C, and after an immunoprecipita-
tion (IP) with anti-CDK2 antibodies kinase assays were per-
formed (top). One-half of the anti-CDK2 immunoprecipitate
was analyzed by immunoblotting with anti-p21 antibodies
(middle). In parallel, an immunoprecipitate with anti-cyclin E
antibodies was analyzed by immunoblotting with anti-16E7 an-
tibodies (bottom). (B) Recombinant PCNA (50 ng) was coincu-
bated with GST–p21 (100 ng), immobilized on glutathione–
Sepharose alone or in the presence of increasing amounts (200,
400, 800 ng) of His–16E7, and the PCNA bound to GST–p21
beads was analyzed by immunoblotting with anti-PCNA anti-
bodies. Lane 1 represents 10% of the input.
Inactivation of p21 by HPV-16 E7
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that was impaired in its ability to inhibit cyclin A-, but
not cyclin E-associated CDK activity (Su et al. 1995).
Also unique among the CIP/KIP inhibitors is the abil-
ity of p21 to bind PCNA through carboxy-terminal se-
quences that overlap Cy2. In proliferating normal diploid
human cells, the p21 bound to active CDK/cyclin com-
plexes is also bound to PCNA (Zhang et al. 1994). Our
results raise the interesting possibility that binding of
proteins to the carboxyl terminus of p21, perhaps spe-
cifically blocking the Cy2 site, may modulate the activ-
ity of p21 on CDK/cyclin complexes. In normal prolif-
erating cells, the Cy2 site is occupied by PCNA; even
normal proliferating fibroblasts expressing 16E7 showed
no detectable disruption of CDK/cyclin/p21/PCNA
complexes (Xiong et al. 1996), consistent with our obser-
vations that PCNA bound p21 more avidly than 16E7
(data not shown). In response to DNA damage or epithe-
lial cell differentiation, the levels of p21 may exceed
those of PCNA, resulting in inactive CDK/cyclin com-
plexes in normal cells. However, in 16E7-expressing
cells, binding of 16E7 to the carboxyl terminus of p21
may promote the accumulation of active CDK/cyclin/
p21 complexes, possibly also by enhancing the associa-
tion between CDK and cyclin subunits (Harper et al.
1995; LaBaer et al. 1997). This model predicts that the
16E7–p21 interaction would be important to overcome
G1 arrest and may not normally occur in proliferative
conditions. Interestingly, p21 with a single amino acid
change at position 94, isolated from a human breast car-
cinoma, was found to have impaired CDK-inhibitory ac-
tivity despite unaltered binding to CDK complexes and
PCNA (Balbı´n et al. 1996), suggesting also that alter-
ations in the carboxyl terminus of p21 can modulate
CDK activity. It has been shown, for example, that free
p21 lacks any stable tertiary structure, but upon binding
to a CDK/cyclin complex, p21 adopts an ordered struc-
ture (Kriwacki et al. 1996). Thus, it is possible that the
16E7–p21 interaction could result in a structural alter-
ation of p21 that leads to reactivation of the CDK/cyclin
complex.
16E7 also impeded the ability of p21 to inhibit PCNA-
dependent DNA replication, probably by a competitive
mechanism. The structure of the p21–PCNA complex
(Gulbis et al. 1996) provided evidence for the possibility
that p21 masked elements on PCNA that are required for
binding of components of the polymerase assembly,
whereas the loading of PCNA onto DNA and the ability
of PCNA to move along DNA appeared not to be affected
by p21 (Podust et al. 1995). The removal of p21 from
PCNA by 16E7 may explain the block of p21 inhibition
of PCNA-dependent DNA replication, thereby allowing
PCNA to function in viral DNA replication.
In contrast to the effect of 16E7, the nononcogenic 6E7
had a reduced ability to relieve p21 inhibition in vitro,
and 6E7 did not overcome a p21-mediated cell cycle ar-
rest in vivo (Demers et al. 1994). In agreement with these
data, the organization of 6E7-expressing keratinocytes in
organotypic raft cultures was not markedly different
from normal epithelium, and only a slight increase in
proliferation was observed (Halbert et al. 1992). How-
ever, benign warts caused by HPV-6 infection are hyper-
proliferative, suggesting that 6E7 can block suprabasal
quiescence. It is possible that the ability of 6E7 to allow
PCNA-dependent DNA replication might be sufficient
for a slow increase in proliferation yet too weak to be
readily detected in the p21 inhibition assays used in our
studies. Because of the difficulty in identifying assays in
which 6E7 is equivalent in activity to 16E7, we cannot
rule out the possibility that our preparations of 6E7 were
suboptimal.
The ability of 16E7 to abrogate growth arrest in previ-
ous experiments was shown to be complicated and
mapped to three regions of 16E7, all of which have been
implicated in the transforming mechanism of 16E7 (De-
mers et al. 1996). A mutation in the carboxyl terminus of
16E7 did not bypass growth arrest signals; however, 16E7
proteins with an intact carboxyl terminus, but altered
conserved regions I or II, also failed to bypass growth
arrest (Demers et al. 1996). These data suggest that under
the experimental conditions used, either the inactiva-
tion of p21 by 16E7 was not sufficient to bypass the G1
arrest or they could provide evidence for multiple do-
mains in 16E7 contributing to the inactivation of p21. In
vivo, it is likely that the release of E2F from RB and the
inactivation of p21 controls on both CDK/cyclin and
PCNA activities are all necessary for the ability of 16E7
to bypass cell cycle arrest signals.
16E7 bypassed a transforming growth factor-b (TGF-
b)-induced growth arrest (Pietenpol et al. 1990; Demers
et al. 1996), suggesting that 16E7 might also inactivate
other CDK inhibitors. Recently, the carboxy-terminal
sequences of 16E7 were shown to bind to and inactivate
p27 (Zerfass-Thome et al. 1996; data not shown), but the
site in p27 to which 16E7 bound and the underlying
mechanism have not been analyzed. The adenovirus E1A
oncoprotein was also shown to abrogate the CDK-inhibi-
tory function of p27 (Mal et al. 1996). E1A bound to the
carboxyl terminus of p27 and prevented the association
of p27 with CDK/cyclin complexes. At present, it is dif-
ficult to propose a conserved mechanism; the carboxy-
termini of p21 and p27 share no obvious homology, and
although the domain of E1A that interacts with p27 has
not been defined, the carboxyl terminus of 16E7 does not
have recognizable homology with E1A. In a broader per-
spective, these findings suggest that DNA tumor viruses
have evolved diverse strategies with the common goal of
counteracting CIP/KIP family CDK inhibitors.
Conclusions
We propose a model in which the dual inactivation of
p21 in cells by 16E7 is a means to maintain high CDK2/
cyclin E activity and allow DNA replication. For HPV-
16, whose survival in host cells depends critically on
PCNA-dependent DNA replication, this likely repre-
sents a central, previously unrecognized pathway. Be-
cause p21 is capable of inhibiting E2F activity in the
absence of functional RB (Dimri et al. 1996), the inacti-
vation of p21 by 16E7 may be a further safeguard to pre-
serve E2F activity. The positive correlation between p21
Funk et al.
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inactivation and the transforming ability of different
HPV types (16 vs. 6) underscores the significance this
mechanism may have to antagonize cell cycle arrest sig-
nals and thereby promote genetic instability during
HPV-induced cancer progression. Because p21 was also
recently shown to be involved in S/M coupling (Wald-
man et al. 1996) it is tempting to speculate that 16E7
may also affect this property of p21, thus allowing cells
to become polyploid.
Finally, our results raise the intriguing possibility that
cellular proteins exist that share the ability of 16E7 to
interact with the carboxyl terminus of p21 and thereby
modulate its dual inhibitory activities. This novel mode
of regulation of p21 activities, and consequently of the
G1-to-S-phase transition and PCNA-dependent DNA
replication, may represent an important mechanism of
balancing the effects of p21 in human cells. The abroga-
tion of a p53-induced cell cycle arrest by cellular onco-
proteins such as c-Myc (Hermeking et al. 1995) could
involve the induction of cellular inhibitors of p21 that
might contribute to the development of cancer.
Materials and methods
Cell cultures
Normal human keratinocytes were prepared from infant fore-
skins and cultured in Keratinocyte Serum-Free Medium
(GIBCO BRL) as described (Demers et al. 1994). Retroviruses
and generation of retrovirally infected cells were described in
detail (Demers et al. 1994, 1996). Subconfluent cells were
treated with actinomycin D (2.5 nM) for 24 hr. Cells were har-
vested, and extracts for kinase assays and flow cytometry were
prepared as described (Demers et al. 1994; Hermeking et al.
1995). For metabolic labeling, the cells were grown in cysteine-
and methionine-free medium (Clonetics) for 30 min and in the
presence of 8.14 MBq/ml of [35S]Protein Labeling Mix (NEN
DuPont) for 2 hr directly prior to harvesting.
Mutational analysis and protein purification
pGEX-2T HPV-16 E7 was created by cloning a PCR fragment of
HPV-16 coordinates 562–858 into the BamHI and EcoRI sites of
pGEX-2T (Pharmacia). pGEX-2T HPV-16 E7N(D40–98) and
16E7C(D1–39) were created using pGEX-2T HPV-16 E7 as a tem-
plate for PCR primers that produced HPV-16 fragments with
coordinates from 562 to 678 and 679 to 858, repectively. These
were cloned into the BamHI and EcoRI sites of pGEX-2T. His–
HPV-16 E7 and HPV-6 E7 were generated by PCR using pGEX-
2T and pLXSN as templates, respectively. The resulting 16E7
open reading frame (ORF) (562–858) and 6E7 ORF (526–994)
were cloned into the BamHI site of pET-16b (Novagen). Prepa-
rations of His–p21 and PCNA have been described earlier (Waga
et al. 1994a,b). His–cyclin E and His–CDK2 were gifts from J.M.
Roberts (FHCRC). The plasmids for GST–p21, GST–p21N(1–
90), and GST–p21C(87–164) were gifts from A. Dutta (Chen et
al. 1995). To generate the plasmids used for in vitro translation
of His–p21 carboxy-terminal truncations the XbaI fragment
containing full length His–p21 from the Escherichia coli expres-
sion plasmid for His–p21 (Waga et al. 1994b) was cloned into the
XbaI site of pRcCMV vector (Invitrogen). Then, the ApaI frag-
ment containing the carboxy-terminal half of p21 in this pRc-
CMV-based construct was replaced by the PCR-amplified frag-
ment encoding each truncated carboxy-terminal region of p21.
The plasmids expressing GST–p21(139–164) and GST–p21(149–
164) were constructed by the insertion of the PCR-amplified
fragment encoding the respective amino acids of p21 into the
BamHI site of pGEX-2TK plasmid (Pharmacia). All other cD-
NAs encoding wild-type or mutant proteins (Fig. 5C; data not
shown) were cloned into pBS. The correct sequences of all con-
structs were confirmed by dideoxy sequencing. GST proteins
were expressed in E. coli [BL21(DE3)] and purified from cell
lysates by binding to glutathione–Sepharose 4B (Pharmacia) ac-
cording to the manufacturer’s instructions. To generate His–
cyclin E/CDK2 for kinase assays, Sf9 insect cells were coin-
fected with baculovirus constructs encoding His–cyclin
E/CDK2 (gift from J.M. Roberts), harvested 2 days postinfec-
tion, and the pellet was lysed in 10 mM HEPES (pH 7.4), 10 mM
NaCl, 1 mM EDTA, 2 mM DTT, and 0.1 mM PMSF, followed by
centrifugation at 14000g for 20 min. The other His-tagged pro-
teins (except p21) were expressed in E. coli [BL21(DE3)]. All
His-tagged proteins were purified from the insoluble fraction
using a Ni–NTA column (Qiagen) according to the manufactur-
er’s instructions. The GST fusion proteins were dialyzed against
a buffer containing 5 mM Tris-Cl (pH 7.5), 10 mM MgCl2, 70 mM
NaCl, and the His-tagged proteins were dialyzed against a buffer
containing 25 mM Tris-Cl (pH 7.5), 10% glycerol, 1 mM EDTA,
1 mM DTT, 0.01% NP-40, and 100 mM NaCl. All purified pro-
teins were analyzed by SDS-PAGE and Coomassie or silver
staining.
Binding assays, immunoprecipitations, and immunoblotting
For in vitro binding reactions, the GST proteins immobilized on
glutathione–Sepharose 4B were incubated with His or IVT pro-
teins for 1 hr at room temperature in binding buffer (20 mM
HEPES at pH 7.4, 150 mM NaCl, 10% glycerol, 0.05% NP-40)
and washed extensively with the binding buffer. The bound
proteins were separated by SDS-PAGE, and one half of the
sample was analyzed by Coomassie staining and the other half
by immunoblotting or fluorography. In vitro transcription and
translation of pBS plasmids was performed with the T3/T7 Ri-
bonuclease Combination System (Promega) in wheat germ ex-
tracts (Promega) according to the manufacturer’s instructions.
Immunoblotting was done as described (Hermeking et al. 1995)
using the following antibodies: anti-p53 mAb (Ab-6, Oncogene
Sciences), anti-p21 mAb (Ab-1, Calbiochem), anti-His pAb (H-
15, Santa Cruz), anti-16E7 mAb (8C9, gift from Zymed Labora-
tories), and anti-PCNA mAb (PC10). To determine the in vivo
association of 16E7 and p21 immunoprecipitations of metaboli-
cally labeled cells using anti-16E7 polyclonal antibodies (Dem-
ers et al. 1996) or anti-p21 polyclonal antibodies (gift from D.
Beach, Cold Spring Harbor Laboratory) were carried out under
consecutive low- and high-stringency conditions as described in
detail (Blackwood et al. 1992).
Kinase assays
In vitro kinase assays with cell extracts were performed essen-
tially as described in detail (Hermeking et al. 1995) using poly-
clonal anti-cyclin E antibodies (gift from J.M. Roberts) or poly-
clonal anti-CDK2 antibodies (M2, Santa Cruz) for immunopre-
cipitations. For in vitro restoration of CDK activity, GST–16E7
was added to cell extracts prior to the immunoprecipitation and
incubated for 1 hr at room temperature; then kinase reactions
were performed after extensive washing of the precipitate. For
kinase reactions with purified CDK2/cyclin E complexes (2 ng/
reaction), p21 and E7 proteins were preincubated for 1 hr at
room temperature, then mixed and further preincubated with
His–cyclin E/CDK2 in kinase buffer for 20 min on ice prior to
Inactivation of p21 by HPV-16 E7
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kinase reactions. In all reactions histone H1 (2.5 µg; Boehringer)
was used as the substrate. The reactions were analyzed by SDS-
PAGE followed by autoradiography and PhosphorImager (Mo-
lecular Dynamics) analysis.
Replication assays
PCNA-activated DNA synthesis with oligo(dT)/poly(dA) as
primer template was carried out as described (Tsurimoto and
Stillman 1991), except that 30 mM HEPES–NaOH (pH 6.6) and
80 µM (in nucleotide) oligo(dT)/poly(dA) (19:1) were used. SV40
DNA replication with the extracts of 293 cells was performed as
described (Stillman and Gluzman 1985). Measurement of incor-
porated nucleotides and analysis of replication products were
done as described previously (Tsurimoto and Stillman 1991;
Waga et al. 1994a). Preincubation of E7 and p21 prior to DNA
synthesis was carried out in a buffer containing 25 mM Tris-HCl
(pH 7.5), 10% glycerol, 1 mM EDTA, 0.01% NP-40, 1 mM DTT,
and 100 mM (Fig. 2A) or 60 mM (Figs. 2B and 6B) NaCl. Prepa-
rations of DNA polymerase d have been described (Waga et al.
1994a,b).
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